[1]
|
U. Lerner, “Bone Remodeling in Postmenopausal Osteoporosis,” Journal of Dental Research, Vol. 85, No. 7, 2006, pp. 584-595. doi:10.1177/154405910608500703
|
[2]
|
P. Downey and M. Siegel, “Bone Biology and the Clinical Implications for Osteoporosis,” Physical Therapy, Vol. 86, No. 1, 2006, pp. 77-91.
doi:10.1016/j.coph.2005.06.005
|
[3]
|
P. Kostenuik, “Osteoprotegerin and RANKL Regulate Bone Resorption, Density, Geometery and Strength,” Current Opinion in Pharmacology, Vol. 5, No. 6, 2005, pp. 618-625.
|
[4]
|
B. Boyce and L. Xing, “Biology of RANK, RANKL, and Osteoprotegerin,” Arthritis Research & Therapy, Vol. 9, Suppl. 1, 2007, p. S1. doi:10.1186/ar2165
|
[5]
|
E. Canalis, “Insulin-Like Growth Factors and Osteoporosis,” Bone, Vol. 21, No. 3, 1997, pp. 215-216.
doi:10.1016/S8756-3282(97)00150-6
|
[6]
|
M. Zhang, S. Xuan, M. Bouxsein, et al., “OsteoblastSpecific Knockout of the Insulin-Like Growth Factor (IGF) Receptor Gene Reveals an Essential Role of IGF Signaling in Bone Matrix Mineralization,” The Journal of Biological Chemistry, Vol. 277, No. 46, 2002, pp. 44005-44012. doi:10.1074/jbc.M208265200
|
[7]
|
T. Dowd, J. Rosen and C. Gundberg, “The Three-Dimensional Structure of Bovine Calcium Ion-Bound Osteocalcin Using 1H NMR Spectroscopy,” Biochemistry, Vol. 42, No. 25, 2003, pp. 7769-7779.
doi:10.1021/bi034470s
|
[8]
|
N. Lee, H. Sowa, E. Hinoi, et al., “Endocrine Regulation of Energy Metabolism by the Skeleton,” Cell, Vol. 130, No. 3, 2007, pp. 456-469. doi:10.1016/j.cell.2007.05.047
|
[9]
|
K. Wongdee and N. Charoenphandhu, “Osteoporosis in Diabetes Mellitus: Possible Cellular and Molecular Mechanisms,” World Journal of Diabetes, Vol. 2, No. 3, 2011, pp. 41-48. doi:10.4239/wjd.v2.i3.41
|
[10]
|
T. Yamaguchi, “Bone Fragility in Type 2 Diabetes Mellitus,” World Journal of Orthopaedics, Vol. 1, No. 1, 2010, pp. 3-9. doi:10.5312/wjo.v1.i1.3
|
[11]
|
M. Petit, M. Paudel, B. Taylor, et al., “Bone Mass and Strength in Older Men with Type 2 Diabetes: The Osteoporotic Fractures in Men Study,” Journal of Bone and Mineral Research, Vol. 25, No. 2, 2010, pp. 285-291.
doi:10.1359/jbmr.090725
|
[12]
|
T. Yamaguchi, I. Kanazawa, M. Yamamoto, et al., “Associations between Components of the Metabolic Syndrome versus Bone Mineral Density and Vertebral Fractures in Patients with Type 2 Diabetes,” Bone, Vol. 45, No. 2, 2009, pp. 174-179.
doi:10.1016/j.bone.2009.05.003
|
[13]
|
S. Yaturu, S. Humphrey, C. Landry and S. Jain, “Decreased Bone Mineral Density in Men with Metabolic Syndrome Alone and with Type 2 Diabetes,” Medical Science Monitor, Vol. 15, No. 1, 2009, pp. 5-9.
|
[14]
|
P. Trinder, “Determination of Glucose in Blood Using Glucose Oxidase with an Alternative Oxygen Acceptor,” Annals of Clinical Biochemistry, Vol. 6, No. 2, 1969, pp. 24-27.
|
[15]
|
E. Matteucci, V. Cinapri, L. Rossi, et al., “Glycated Hemoglobin Measurement: Intermethod Comparison,” Diabetes, Nutrition & Metabolism, Vol. 14, No. 4, 2001, pp. 217-219.
|
[16]
|
S. Laxmayya, P. Sandhya and M. Umesh, “Serum Calcium Measurement: Total versus Free (Ionized) Calcium” Indian Journal of Clinical Biochemistry, Vol. 20, No. 2, 2005, pp. 158-161. doi:10.1007/BF02867418
|
[17]
|
P. Schnatz, K. Marakovits and D. O’Sullivan, “Assessment of Postmenopausal Women and Significant Risk Factors for Osteoporosis,” Obstetrical & Gynecological Survey, Vol. 65, No. 9, 2010, pp. 591-596.
doi:10.1097/OGX.0b013e3181fc6d30
|
[18]
|
H. Zhao, J. Liu, G. Ning, et al., “Relationships between Insulin-Like Growth Factor-I (IGF-I) and OPG, RANKL, Bone Mineral Density in Healthy Chinese Women,” Osteoporosis International, Vol. 19, No. 2, 2008, pp. 221-226. doi:10.1007/s00198-007-0440-y
|
[19]
|
P. Garnero, E. Sornay-Rendu and P. Delmas, “Low Serum IGF-1 and Occurrence of Osteoporotic Fractures in Postmenopausal Women,” Lancet, Vol. 355, No. 9207, 2000, pp. 898-899. doi:10.1016/S0140-6736(99)05463-X
|
[20]
|
I. Kanazawa, T. Yamaguchi, M. Yamamoto, et al., “Serum Insulin-Like Growth Factor-I level is Associated with the Presence of Vertebral Fractures in Postmenopausal Women with Type 2 Diabetes Mellitus,” Osteoporosis International, Vol. 18, No. 12, 2007, pp. 1675-1681. doi:10.1007/s00198-007-0430-0
|
[21]
|
C. Posaci, S. Altunyurt, H. Islekel and A. Onvural, “Effects of HRT on Serum Levels of IGF-I in Postmenopausal Women,” Maturitas, Vol. 40, No. 1, 2001, pp. 69-74. doi:10.1016/S0378-5122(01)00230-4
|
[22]
|
E. Poehlman, M. Toth, P. Ades, C. Rosen, “Menopause Associated Changes in Plasma Lipids, Insulin-Like Growth Factor-I, and Blood Pressure: A Longitudinal Study,” European Journal of Clinical Investigation, Vol. 27, No. 4, 1997, pp. 322-326.
doi:10.1046/j.1365-2362.1997.1160662.x
|
[23]
|
S. Yakar, C. J. Rosen, “From Mouse to Man: Redefining the Role of Insulin-Like Growth Factor-I in the Acquisition of Bone Mass,” Experimental Biology and Medicine (Maywood), Vol. 228, No. 3, 2003, pp. 245-252.
|
[24]
|
T. Ueland, “GH/IGF-I and Bone Resorption in Vivo and in Vitro,” European Journal of Endocrinology, Vol. 152, No. 3, 2005, pp. 327-332. doi:10.1530/eje.1.01874
|
[25]
|
B. Abrahamsen, J. Hjelmborg, P. Kostenuik, et al., “Circulating Amounts of Osteoprotegerin and RANKL: Genetic Influence and Relationship with BMD Assessed in Female Twins” Bone, Vol. 36, No. 4, 2005, pp. 727-735.
doi:10.1016/j.bone.2004.12.015
|
[26]
|
S. Trofimov, I. Pantsulaia, E. Kobyliansky and G. Livshits, “Circulating Levels of Receptor Activator of Nuclear Factor κB Ligand/Osteoprotegerin/Macrophage-Colony Stimulating Factor in a Presumably Healthy Human Population,” European Journal of Endocrinology, Vol. 150, No. 3, 2004, pp. 305-311. doi:10.1530/eje.0.1500305
|
[27]
|
D. Vega, N. Maalouf and K. Sakhaee, “CLINICAL Review #: the Role of Receptor Activator of Nuclear FactorKappaB (RANK)/RANK Ligand/Osteoprotegerin: Clinical Implications,” The Journal of Clinical Endocrinology & Metabolism, Vol. 92, No. 12, 2007, pp. 4514-4521.
doi:10.1210/jc.2007-0646
|
[28]
|
W. Browner, L. Lui and S. Cummings, “Association of Serum Osteoprotegerin Levels with Diabetes, Strike, Bone Density, Fractures and Mortality in Elderly Women,” The Journal of Clinical Endocrinology & Metabolism, Vol. 86, No. 2, 2001, pp. 631-637.
doi:10.1210/jc.86.2.631
|
[29]
|
G. D. Xiang, L. Xu, L. S. Zhao, et al., “The Relationship between Plasma Osteoprotegerin and Endothelium-Dependent Arterial Dilation in Type 2 Diabetes,” Diabetes, Vol. 55, No. 7, 2006, pp. 2126-2131.
doi:10.2337/db06-0231
|
[30]
|
I. Nabipour, M. Kalantarhormozi, B. Larijani, et al., “Osteoprotegerin in Relation to Type 2 Diabetes Mellitus and the Metabolic Syndrome in Postmenopausal Women,” Metabolism, Vol. 59, No. 5, 2010, pp. 742-747.
doi:10.1016/j.metabol.2009.09.019
|
[31]
|
N. Bucay, I. Sarosi, C. Dunstan, et al., “Osteoprotegerin-Deficient Mice Develop Early Onset Osteoporosis and Arterial Calcification,” Genes & Development, Vol. 12, No. 9, 1998, pp. 1260-1268. doi:10.1101/gad.12.9.1260
|
[32]
|
R. Mogelvang, S. Pedersen, A. Flyvbjerg, et al., “Comparison of Osteoprotegerin to Traditional Atherosclerotic Risk Factors and High-Sensitivity C-Reactive Protein for Diagnosis of Atherosclerosis,” American Journal of Cardiology, Vol. 109, No. 4, 2012, pp. 515-520.
doi:10.1016/j.amjcard.2011.09.043
|
[33]
|
B. Guldiken, S. Guldiken, B. Turgut, et al., “Serum Osteoprotegerin Levels in Patients with Acute Atherothrombotic Stroke and Lacunar Infarct,” Thrombosis Research, Vol. 120, No. 4, 2007, pp. 511-516.
doi:10.1016/j.thromres.2006.12.004
|
[34]
|
S. Ziegler, S. Kudlacek, A. Luger and E. Minar, “Osteoprotegerin Plasma Concentration Correlates with Severity of Peripheral Artery Disease,” Arteriosclerosis, Vol. 182, No. 1, 2005, pp. 175-180.
doi:10.1016/j.atherosclerosis.2005.01.042
|
[35]
|
P. Collin-Osdoby, L. Rothe, F. Anderson, et al., “Receptor Activator of NF-κB and Osteoprotegerin Expression by Human Microvascular Endothelial Cells, Regulation by Inflammatory Cytokines, and Role in Human Osteoclastogenesis,” The Journal of Biological Chemistry, Vol. 276, No. 23, 2001, pp. 20659-20672.
doi:10.1074/jbc.M010153200
|
[36]
|
L. Lum, B. Wong, R. Josien, J. Becherer, et al., “Evidence for a Role of a Tumor Necrosis Factor-Alpha (TNF-Alpha)-Converting Enzyme-Like Protease in Shedding of TRANCE, a TNF Family Member Involved in Osteoclastogenesis and Dentritic Cell Survival,” The Journal of Biological Chemistry, Vol. 274, No. 19, 1999, pp. 13613-13618. doi:10.1074/jbc.274.19.13613
|
[37]
|
J. Rubin, C. Ackert-Bicknell, L. Zhu, X. Fan, et al., “IGF-1 Regulates Osteoprotegerin (OPG) and Receptor Activator of Nuclear Factor κB Ligand in Vitro and OPG in Vivo,” The Journal of Clinical Endocrinology & Metabolism, Vol. 87, No. 9, 2002, pp. 4273-4279.
doi:10.1210/jc.2002-020656
|
[38]
|
J. A. Im, B. P. Yu, J. Y. Jeon and S. H. Kim, “Relationship between Osteocalcin and Glucose Metabolism in Postmenopausal Women,” Clinica Chimica Acta, Vol. 396, No. 1-2, 2008, pp. 66-69.
doi:10.1016/j.cca.2008.07.001
|
[39]
|
I. Kanazawa, T. Yamaguchi, Y. Tada, et al., “Serum Osteocalcin Level Is Positively Associated with Insulin Sensitivity and Secretion in Patients with Type 2 Diabetes,” Bone, Vol. 48, No. 4, 2011, pp. 720-725.
doi:10.1016/j.bone.2010.12.020
|
[40]
|
L. McCabe, “Understanding the Pathology and Mechanisms of Type 1 Diabetic Bone Loss,” Journal of Cellular Biochemistry, Vol. 102, No. 6, 2007, pp. 1343-1357.
doi:10.1002/jcb.21573
|